Project Grant R44CA291444
Award Date
6/3/25
Completion Date
5/31/27
Dollars Obligated
$772K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,024,967.00 to Celdara Medical, LLC for the development of CM-HZ01, a novel interleukin-2 (IL-2) based therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 to Investigational New Drug (IND) status, with the goal of providing an improved immunotherapy option for patients with this deadly form of skin cancer. The award period is from January 1, 2025,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award, titled "METABOLIC CONTROL OF MALIGNANT FATES IN LUNG CANCER", is funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $730,400 award, with a period of performance from December 1, 2024 to November 30, 2029, will support research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York, NY. The research aims to determine how specific...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $730,407 to support research investigating how inhibiting the ULK1 protein kinase, which controls autophagy, can rewire tumor and immune cell metabolism in lung cancer. The research aims to establish the role of ULK1 in lung tumor metabolism, dissect the impact of ULK1 inhibition on T cell metabolism, and explore the therapeutic potential of a novel ULK1 inhibitor compound (ULK-101)...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California provides $650,450 in funding from July 1, 2025 to June 30, 2030 to develop a novel TCR-engineered CD4+ T cell immunotherapy product for the treatment of lung cancer. The key products and services to be delivered under this award include: 1) Determining the mechanisms by which the MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer...
This federal Project Grant award of $1,506,651 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research at Virginia Commonwealth University (VCU) to evaluate a new agent called PEPDG278D for overcoming drug resistance in non-small cell lung cancer (NSCLC). The key objective is to determine if PEPDG278D can effectively induce the degradation of epidermal growth factor receptor (EGFR) and HER2, which are oncogenic drivers frequently overexpressed or mutated in...
The National Cancer Institute (NCI) awarded a $1,408,844 Project Grant (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY to investigate the theranostic potential of Delta-Like Ligand 3 (DLL3)-targeting agents in high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate (neuroendocrine prostate cancer). The project aims to utilize a DLL3-targeted radiolabeled monoclonal antibody for non-invasive diagnosis...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $798,512 to Luminary Therapeutics, Inc. to develop an innovative allogeneic gamma/delta CAR T-cell therapy targeting epithelial ovarian carcinoma. The key products and services to be delivered under this award include: Engineering an "armored split CAR" that combines two CAR molecules targeting different antigens (mesothelin and chondroitin sulfate proteoglycan-4) on a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing the efficacy of KRAS inhibitor therapies for cancer treatment. The key focus is to identify synthetic lethal genes and resistance mechanisms that can be targeted to improve outcomes for patients with KRAS-mutated cancers, such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer....
This federal Project Grant award of $696,569 from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program supports research by New York University (NYU) School of Medicine to develop novel therapeutic strategies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment; 2) develop antibody-based therapies that target LCN2 and assess their efficacy as monotherapy and in combination...